{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T10:10:04Z","timestamp":1772878204931,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,5,3]],"date-time":"2011-05-03T00:00:00Z","timestamp":1304380800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1007\/s00213-011-2315-3","type":"journal-article","created":{"date-parts":[[2011,5,2]],"date-time":"2011-05-02T06:53:28Z","timestamp":1304319208000},"page":"341-345","source":"Crossref","is-referenced-by-count":17,"title":["Dipyridamole monotherapy in schizophrenia"],"prefix":"10.1007","volume":"218","author":[{"given":"Ikwunga","family":"Wonodi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirekatur V.","family":"Gopinath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judy","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helene","family":"Adami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. Elliot","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Allen-Emerson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert P.","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunvant K.","family":"Thaker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,5,3]]},"reference":[{"key":"2315_CR1","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2710.2000.00273.x","volume":"25","author":"S Akhondzadeh","year":"2000","unstructured":"Akhondzadeh S et al (2000) Dipyridamole in the treatment of schizophrenia: adenosine-dopamine receptor interactions. J Clin Pharm Ther 25:131\u2013137","journal-title":"J Clin Pharm Ther"},{"key":"2315_CR2","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.pnpbp.2004.11.008","volume":"29","author":"S Akhondzadeh","year":"2005","unstructured":"Akhondzadeh S et al (2005) Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 29:253\u2013259","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2315_CR3","volume-title":"The scale for the assessment of positive symptoms (SAPS)","author":"NC Andreasen","year":"1984","unstructured":"Andreasen NC (1984) The scale for the assessment of positive symptoms (SAPS). University of Iowa, Iowa City"},{"key":"2315_CR4","unstructured":"Boison D, et al. (2011) Adenosine hypothesis of schizophrenia \u2014 opportunities for pharmacotherapy. Neuropharmacology"},{"key":"2315_CR5","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1046\/j.1365-2710.2001.00335.x","volume":"26","author":"MG Brunstein","year":"2001","unstructured":"Brunstein MG et al (2001) Therapeutic benefit of adjunctive dipyridamole in schizophrenia is probably due to adenosine\u2013glutamate interactions. J Clin Pharm Ther 26:155\u2013156","journal-title":"J Clin Pharm Ther"},{"key":"2315_CR6","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0893-133X(88)90012-7","volume":"1","author":"A Carlsson","year":"1988","unstructured":"Carlsson A (1988) The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1:179\u2013186","journal-title":"Neuropsychopharmacology"},{"key":"2315_CR7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0165-1781(97)03031-X","volume":"70","author":"SL Cassady","year":"1997","unstructured":"Cassady SL et al (1997) The Maryland psychatric research center scale for the characterization of involuntary movements. Psychiatry Res 70:21\u201337","journal-title":"Psychiatry Res"},{"key":"2315_CR8","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1358\/dnp.2003.16.9.829342","volume":"16","author":"JF Chen","year":"2003","unstructured":"Chen JF (2003) The adenosine A(2A) receptor as an attractive target for Parkinson's disease treatment. Drug News Perspect 16:597\u2013604","journal-title":"Drug News Perspect"},{"key":"2315_CR9","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s11302-008-9100-8","volume":"4","author":"M Cieslak","year":"2008","unstructured":"Cieslak M et al (2008) Adenosine A(2A) receptors in Parkinson\u2019s disease treatment. Purinergic Signal 4:305\u2013312","journal-title":"Purinergic Signal"},{"key":"2315_CR10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/WNF.0b013e31816f2795","volume":"32","author":"RR Conley","year":"2009","unstructured":"Conley RR et al (2009) The effects of galantamine on psychopathology in chronic stable schizophrenia. Clin Neuropharmacol 32:69\u201374","journal-title":"Clin Neuropharmacol"},{"key":"2315_CR11","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/00001756-200303030-00003","volume":"14","author":"J Deckert","year":"2003","unstructured":"Deckert J et al (2003) Up-regulation of striatal adenosine A(2A) receptors in schizophrenia. Neuroreport 14:313\u2013316","journal-title":"Neuroreport"},{"key":"2315_CR12","first-page":"112","volume":"110","author":"J Delay","year":"1952","unstructured":"Delay J et al (1952) Utilization therpeutique psychiatrique d'une phenothiazine d'action centrale elective. Ann M\u00e9d Psychol 110:112\u2013117","journal-title":"Ann M\u00e9d Psychol"},{"key":"2315_CR13","doi-asserted-by":"crossref","first-page":"5611","DOI":"10.1523\/JNEUROSCI.5378-07.2008","volume":"28","author":"CC Fernandes","year":"2008","unstructured":"Fernandes CC et al (2008) Postsynaptic action of brain-derived neurotrophic factor attenuates alpha7 nicotinic acetylcholine receptor-mediated responses in hippocampal interneurons. J Neurosci 28:5611\u20135618","journal-title":"J Neurosci"},{"key":"2315_CR14","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s002130050380","volume":"133","author":"S Ferre","year":"1997","unstructured":"Ferre S (1997) Adenosine\u2013dopamine interactions in the ventral striatum. Implications for the treatment of schizophrenia. Psychopharmacology (Berl) 133:107\u2013120","journal-title":"Psychopharmacology (Berl)"},{"key":"2315_CR15","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/0306-4522(94)90521-5","volume":"63","author":"S Ferre","year":"1994","unstructured":"Ferre S et al (1994) Antagonistic interaction between adenosine A2A receptors and dopamine D2 receptors in the ventral striopallidal system. Implications for the treatment of schizophrenia. Neuroscience 63:765\u2013773","journal-title":"Neuroscience"},{"key":"2315_CR16","volume-title":"Structured Clinical Interview for DSM-IV Axis I Disorders","author":"MB First","year":"1997","unstructured":"First MB, Spitzer RL, Gibbon M, Williams JBW (1997) Structured Clinical Interview for DSM-IV Axis I Disorders. American Psychiatric Publishing, Inc., Arlington"},{"key":"2315_CR17","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s00018-003-3269-3","volume":"61","author":"G Fisone","year":"2004","unstructured":"Fisone G et al (2004) Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci 61:857\u2013872","journal-title":"Cell Mol Life Sci"},{"key":"2315_CR18","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1111\/j.1755-5949.2009.00126.x","volume":"16","author":"K Fuxe","year":"2010","unstructured":"Fuxe K et al (2010) Adenosine\u2013dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci Ther 16:e18\u2013e42","journal-title":"CNS Neurosci Ther"},{"key":"2315_CR19","doi-asserted-by":"crossref","unstructured":"Ghaleiha A et al (2011) Correlation of adenosinergic activity with superior efficacy of clozapine for treatment of chronic schizophrenia: a double blind randomised trial. Hum Psychopharmacol.","DOI":"10.1002\/hup.1176"},{"key":"2315_CR20","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1176\/ajp.152.8.1213","volume":"152","author":"DC Goff","year":"1995","unstructured":"Goff DC et al (1995) ose-finding trial of d-cycloserine added to neuroleptics for negative symptoms in schizophrenia. Am J Psychiatry 152:1213\u20131215","journal-title":"Am J Psychiatry"},{"key":"2315_CR21","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1523\/JNEUROSCI.17-14-05271.1997","volume":"17","author":"J Harvey","year":"1997","unstructured":"Harvey J, Lacey MG (1997) A postsynaptic interaction between dopamine D1 and NMDA receptors promotes presynaptic inhibition in the rat nucleus accumbens via adenosine release. J Neurosci 17:5271\u20135280","journal-title":"J Neurosci"},{"key":"2315_CR22","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2165\/00002512-200522060-00002","volume":"22","author":"RA Hauser","year":"2005","unstructured":"Hauser RA, Schwarzschild MA (2005) Adenosine A2A receptor antagonists for Parkinson's disease: rationale, therapeutic potential and clinical experience. Drugs Aging 22:471\u2013482","journal-title":"Drugs Aging"},{"key":"2315_CR23","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/BF00442002","volume":"98","author":"TG Heffner","year":"1989","unstructured":"Heffner TG et al (1989) Comparison of the behavioral effects of adenosine agonists and dopamine antagonists in mice. Psychopharmacology (Berl) 98:31\u201337","journal-title":"Psychopharmacology (Berl)"},{"key":"2315_CR24","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1002\/gps.930070908","volume":"19","author":"R Howard","year":"1992","unstructured":"Howard R, Levy R (1992) Which factors affect treatment response in late paraphrenia? Int J Geriatr Psychiatry 19:667\u2013672","journal-title":"Int J Geriatr Psychiatry"},{"key":"2315_CR25","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0014-2999(95)00668-0","volume":"295","author":"SH Kafka","year":"1996","unstructured":"Kafka SH, Corbett R (1996) Selective adenosine A2A receptor\/dopamine D2 receptor interactions in animal models of schizophrenia. Eur J Pharmacol 295:147\u2013154","journal-title":"Eur J Pharmacol"},{"key":"2315_CR26","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1176\/appi.ajp.157.4.514","volume":"157","author":"S Kapur","year":"2000","unstructured":"Kapur S et al (2000) Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157:514\u2013520","journal-title":"Am J Psychiatry"},{"key":"2315_CR27","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/00004850-200107000-00008","volume":"16","author":"DR Lara","year":"2001","unstructured":"Lara DR et al (2001) Allopurinol augmentation for poorly responsive schizophrenia. Int Clin Psychopharmacol 16:235\u2013237","journal-title":"Int Clin Psychopharmacol"},{"key":"2315_CR28","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.pnpbp.2006.02.002","volume":"30","author":"DR Lara","year":"2006","unstructured":"Lara DR et al (2006) Involvement of adenosine in the neurobiology of schizophrenia and its therapeutic implications. Prog Neuropsychopharmacol Biol Psychiatry 30:617\u2013629","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2315_CR29","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA et al (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209\u20131223","journal-title":"N Engl J Med"},{"key":"2315_CR30","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1006\/geno.1994.1181","volume":"20","author":"M MacCollin","year":"1994","unstructured":"MacCollin M et al (1994) Mapping of a human A2a adenosine receptor (ADORA2) to chromosome 22. Genomics 20:332\u2013333","journal-title":"Genomics"},{"key":"2315_CR31","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1124\/jpet.102.036731","volume":"303","author":"SA Masino","year":"2002","unstructured":"Masino SA et al (2002) Modulation of hippocampal glutamatergic transmission by ATP is dependent on adenosine a(1) receptors. J Pharmacol Exp Ther 303:356\u2013363","journal-title":"J Pharmacol Exp Ther"},{"key":"2315_CR32","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.mp.4001556","volume":"10","author":"S Miyamoto","year":"2005","unstructured":"Miyamoto S et al (2005) Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10:79\u2013104","journal-title":"Mol Psychiatry"},{"key":"2315_CR33","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0304-3940(96)12780-4","volume":"212","author":"M Okada","year":"1996","unstructured":"Okada M et al (1996) Adenosine A1 and A2 receptors modulate extracellular dopamine levels in rat striatum. Neurosci Lett 212:53\u201356","journal-title":"Neurosci Lett"},{"key":"2315_CR34","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1111\/j.1471-4159.2004.02761.x","volume":"91","author":"D Quarta","year":"2004","unstructured":"Quarta D et al (2004) Adenosine receptor-mediated modulation of dopamine release in the nucleus accumbens depends on glutamate neurotransmission and N-methyl-d-aspartate receptor stimulation. J Neurochem 91:873\u2013880","journal-title":"J Neurochem"},{"key":"2315_CR35","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/j.pnpbp.2007.11.021","volume":"32","author":"S Salimi","year":"2008","unstructured":"Salimi S et al (2008) A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 32:726\u2013732","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"2315_CR36","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S0014-2999(99)00088-6","volume":"369","author":"TL Sills","year":"1999","unstructured":"Sills TL et al (1999) The adenosine A1 receptor agonist N 6-cyclopentyladenosine blocks the disruptive effect of phencyclidine on prepulse inhibition of the acoustic startle response in the rat. Eur J Pharmacol 369:325\u2013329","journal-title":"Eur J Pharmacol"},{"key":"2315_CR37","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0361-9230(95)00068-P","volume":"38","author":"M Tariq","year":"1995","unstructured":"Tariq M et al (1995) Dipyridamole attenuates the development of iminodipropionitrile-induced dyskinetic abnormalities in rats. Brain Res Bull 38:31\u201335","journal-title":"Brain Res Bull"},{"key":"2315_CR38","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1124\/mol.104.003376","volume":"67","author":"M Torvinen","year":"2005","unstructured":"Torvinen M et al (2005) Adenosine A2A receptor and dopamine D3 receptor interactions: evidence of functional A2A\/D3 heteromeric complexes. Mol Pharmacol 67:400\u2013407","journal-title":"Mol Pharmacol"},{"key":"2315_CR39","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s002130050614","volume":"137","author":"H Wetzel","year":"1998","unstructured":"Wetzel H et al (1998) Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology \u2014 a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-\/D2-like antagonist. The Amisulpride Study Group. Psychopharmacology (Berl) 137:223\u2013232","journal-title":"Psychopharmacology (Berl)"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-011-2315-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-011-2315-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-011-2315-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T12:27:16Z","timestamp":1560169636000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-011-2315-3"}},"subtitle":["Pilot of a novel treatment approach by modulation of purinergic signaling"],"short-title":[],"issued":{"date-parts":[[2011,5,3]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["2315"],"URL":"https:\/\/doi.org\/10.1007\/s00213-011-2315-3","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,3]]}}}